On December 30, Gelonghui reported that Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary Shanghai Haisco Shengnuo Pharmaceutical Technology Co., Ltd. recently received the "Acceptance Notice" from the National Medical Products Administration for HSK44459 tablets.
HSK44459 tablets are a brand new drug independently developed by the company, with independent intellectual property rights for treating psoriasis and atopic dermatitis. According to the National Medical Products Administration's announcement on the classification and application material requirements for chemical drug registration (No. 44 of 2020), this product falls under Class 1 chemical drugs.
Preclinical research results indicate that this product has clear targets, definite efficacy, and good safety, making it a small molecule drug with significant development potential, a high benefit/risk ratio for clinical application, and a broad clinical application prospect. It is expected to become an effective treatment for psoriasis and atopic dermatitis, addressing the current problem of a shortage of clinical medications. The acceptance obtained this time is for the clinical trial application for the indications of psoriasis and atopic dermatitis.
